Cell Therapy

Since its founding in 2009, Kite Pharma has been an industry leader in the CAR T cell therapy space, powered by our mission to revolutionise the way patients with cancer are treated.

CAR T

CAR T-cell therapy is a one-time treatment that uses the power of a person’s immune system to fight cancer.

Discover CAR T

Learn more about our treatment options

Our Medicines

Yescarta®▼ (axicabtagene ciloleucel)

For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.

Product Information

Tecartus®▼ (brexucabtagene autoleucel)

Has been granted conditional marketing authorisation for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.

Product Information

Tecartus®▼ (brexucabtagene autoleucel)

Has been granted conditional marketing authorisation for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).

Product Information

See all Medicines

Referring patients for
CAR T

Treatment Centres and NHS England Cancer Drugs Fund (CDF) Eligibility criteria.

Learn more

Events and Resources

Upcoming and past events

See our latest events information in the field of haematology.

Go to Events

Resources

Download our expert resources to support your practice and improve patient outcomes.

Go to Resources

Stay up to date

Receive email updates from Gilead, including promotional communications.

References

1. YESCARTA®. SmPC for the United Kingdom. https://www.medicines.org.uk/emc/product/9439/smpc. Accessed: April 2025.
2. TECARTUS®. SmPC for the United Kingdom. https://www.medicines.org.uk/emc/product/11987/smpc. Accessed: April 2025.

June 2025 UKI-TEC-0022

Adverse events should be reported.

For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). For IE, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead to [email protected] or +44(0) 1223 897500 or +353(0) 21 482 5999.